MARKET

PRNAF

PRNAF

Alterity Therapeutics Ltd
OTCPK
0.400
NaN%
Closed 09:30 09/04 EDT
OPEN
--
PREV CLOSE
0.400
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.540
52 WEEK LOW
0.010
MARKET CAP
87.40M
P/E (TTM)
-7.7519
1D
5D
1M
3M
1Y
5Y
1D
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
Barchart · 3d ago
Alterity Therapeutics to Spotlight MSA Program at Cantor Global Healthcare Conference
TipRanks · 3d ago
Alterity Therapeutics Updates Director Equity Holdings After Option Expiry
TipRanks · 4d ago
Alterity Director Peter Marks Converts Options, Lifts Equity Stake
TipRanks · 4d ago
Alterity Therapeutics Seeks ASX Quotation for New Ordinary Shares
TipRanks · 5d ago
Alterity Therapeutics Files 2026 Annual Report and XBRL Data with SEC
TipRanks · 6d ago
Alterity Taps Underwritten ATHO Options to Fund ATH434 MSA Program
TipRanks · 6d ago
Alterity Therapeutics Reaffirmed at Buy as Pivotal Phase 3 Nears; $16 Price Target Maintained
TipRanks · 08/28 18:35
More
About PRNAF
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.

Webull offers Alterity Therapeutics Ltd stock information, including OTCPK: PRNAF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRNAF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRNAF stock methods without spending real money on the virtual paper trading platform.